Is Routine Dosimetry Really Happening?

John J. Sunderland

doi:10.2967/jnumed.124.267830

Article Figures & Data

Tables

View popup

TABLE 1.

Survey Results

Site	Clinical dosimetry?	Billing for SPECT? Dosimetry?	Dosimetry of all clinical patients or subset?	Optional: RPT dosimetry for clinical trials
1	No	Yes (SPECT)	Subset (unspecified)	Yes (internal and external trials)
2	Yes	Yes (SPECT)	Subset (single/compromised kidney function, significant bone mets/lung mets, retreatment)	No response
3	Yes	No	Subset (those who agree to multiple imaging)	No response
4	Yes	Yes (SPECT)	Subset (reduced kidney function, other risk factors)	No response
5	Yes (¹³¹I, no ¹⁷⁷Lu)	Yes (SPECT and dosimetry)	Subset (¹³¹I, suspected lung mets)	No response
6	No	No (not performed)	No	No
7	No	No (not performed)	No	No
8	No	No (not performed)	No	Yes (internal trials)
9	No	No (not performed)	No	Yes (internal trials)
10	No	No (not performed)	No	No
11	Yes	Yes (SPECT and dosimetry)	Subset (attending physician driven)	No
12	Yes (¹³¹I, ⁹⁰Y, ¹³¹I-iobenguane, no ¹⁷⁷Lu)	Yes (SPECT)	Subset (unspecified)	Yes (internal trials)
13	No	No (not performed)	No	Yes (internal trials)
14	Yes	No	Subset (¹³¹I, suspected lung mets, ¹⁷⁷Lu pending)	No
15	Yes	Yes (unspecified)	Subset (all ⁹⁰Y, ¹⁷⁷Lu renal insufficiency, previously treated, borderline marrow function, previously irradiated organs)	Yes (internal and external trials)
16	No	No (not performed)	No	No
17	Yes	Yes (SPECT)	Subset (¹⁷⁷Lu-DOTATATE)	Yes (internal trials)
18	Yes	Yes (SPECT and dosimetry)	Subset (¹³¹I, compromised renal function; ¹⁷⁷Lu, compromised renal function or low blood counts for marrow toxicity)	Yes (internal trials)
19	Yes	Yes (SPECT)	Subset (unspecified)	Yes (internal trials)
20	No	Yes (SPECT)	Subset (¹⁷⁷Lu, all except those who cannot return)	Yes (internal trials)